Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
The antibody was designed and developed at Abzena’s Cambridge, UK,
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Subscribe To Our Newsletter & Stay Updated